Narcolepsy and Syndromes of Primary Excessive Daytime Somnolence

 

 Buy Article Permissions and Reprints

Excessive daytime sleepiness (EDS) or somnolence is common in our patients and in society in general. The most common cause of EDS is “voluntary” sleep restriction. Other common causes include sleep-fragmenting disorders such as the obstructive sleep apnea syndrome. Somewhat less familiar to the clinician are EDS conditions arising from central nervous system dysfunction. Of these so-called primary disorders of somnolence, narcolepsy is the most well known and extensively studied, yet often misunderstood and misdiagnosed. Idiopathic hypersomnia, the recurrent hypersomnias, and EDS associated with nervous system disorders also must be well-understood to provide appropriate evaluation and management of the patient with EDS. This review summarizes the distinguishing features of these clinical syndromes of primary EDS. A brief overview of the pharmacological management of primary EDS is included. Finally, in view of the tremendous advances that have occurred in the past few years in our understanding of the pathophysiology of canine and human narcolepsy, we also highlight these discoveries.

REFERENCES

• 1 Hublin C, Kaprio J, Partinen M et al.. The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort.  Ann Neurol. 1994;  35 709-716
  CrossrefPubMedGoogle Scholar
• 2 Mignot E. Genetic and familial aspects of narcolepsy.  Neurology. 1998;  50(suppl 1) S16-S22
  CrossrefPubMedGoogle Scholar
• 3 International Classification of Sleep Disorders (ICSD) . Diagnostic and Coding Diagnostic Classification Steering Committee (Thorpy MJ, chairman). American Sleep Disorders Association.  Narcolepsy. 1990;  347 38-43
  PubMedGoogle Scholar
• 4 Beusterien K M, Rogers A E, Walsleben J A et al.. Health-related quality of life effects of modafinil for treatment of narcolepsy.  Sleep. 1999;  22 757-765
  PubMedGoogle Scholar
• 5 US Xyrem in Narcolepsy Multi-center Study Group . A randomized, double blind, placebo controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy.  Sleep. 2002;  25 42-49
  CrossrefPubMedGoogle Scholar
• 6 Johns M W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale.  Sleep. 1991;  14 540-545
  Google Scholar
• 7 Honda Y. Clinical features of narcolepsy: Japanese experiences. In: Honda Y, Juji T HLA in Narcolepsy Berlin; Springer-Verlag 1988: 24-57
  Google Scholar
• 8 Gelb M, Guilleminault C, Kraemer H et al.. Stability of cataplexy over several months: information for the design of therapeutic trials.  Sleep. 1994;  17 265-273
  PubMedGoogle Scholar
• 9 Overeem S, Mignot E, van Dijk J G, Lammers G J. Narcolepsy: clinical features, new pathophysiological insights, and future perspectives.  J Clin Neurophysiol. 2001;  18 78-105
  CrossrefPubMedGoogle Scholar
• 10 Nishino S, Ripley B, Overeem S, Lammers G J, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy.  Lancet. 2000;  355 39-40
  CrossrefPubMedGoogle Scholar
• 11 Mignot E, Lammers G J, Ripley B et al.. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.  Arch Neurol. 2002;  59 1553-1562
  CrossrefPubMedGoogle Scholar
• 12 Mignot E. Genetic and familial aspects of narcolepsy.  Neurology. 1998;  50 S16-S22
  CrossrefPubMedGoogle Scholar
• 13 Guilleminault C, Stoohs R, Clerk A, Cetel M, Maistros P. A cause of excessive daytime sleepiness. The upper airway resistance syndrome.  Chest. 1993;  104 781-787
  CrossrefPubMedGoogle Scholar
• 14 Roth B. Narcolepsy and hypersomnia.  Schweiz Arch Neurol Neurochir Psychiatr. 1976;  119 31-41
  PubMedGoogle Scholar
• 15 Aldrich M S. The clinical spectrum of narcolepsy and idiopathic hypersomnia.  Neurology. 1996;  46 393-401
  PubMedGoogle Scholar
• 16 Montplaisir J, Poirier G. HLA in disorders of excessive sleepiness without cataplexy in Canada. In: Honda Y, Juji T HLA in Narcolepsy Berlin; Springer-Verlag 1988: 186
  Google Scholar
• 17 Montplaisir J, De Champlain J, Young S N et al.. Narcolepsy and idiopathic hypersomnia: biogenic amines and related compounds in CSF.  Neurology. 1982;  32 1299-1302
  PubMedGoogle Scholar
• 18 Faull K F, Guilleminault C, Berger P A, Barchas J D. Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomnia.  Ann Neurol. 1983;  13 258-263
  CrossrefPubMedGoogle Scholar
• 19 Faull K F, Thiemann S, King R J, Guilleminault C. Monoamine interactions in narcolepsy and hypersomnia: a preliminary report.  Sleep. 1986;  9 246-249
  PubMedGoogle Scholar
• 20 Bruck D, Parkes J D. A comparison of idiopathic hypersomnia and narcolepsy-cataplexy using self report measures and sleep diary data.  J Neurol Neurosurg Psychiatry. 1996;  60 576-578
  CrossrefPubMedGoogle Scholar
• 21 Bassetti C, Aldrich M S. Idiopathic hypersomnia. A series of 42 patients.  Brain. 1997;  120 1423-1435
  CrossrefPubMedGoogle Scholar
• 22 Billiard M, Dauvilliers Y. Idiopathic hypersomnia.  Sleep Med Rev. 2001;  5 349-358
  CrossrefPubMedGoogle Scholar
• 23 Roth B, Nevsimalova S, Rechtschaffen A. Hypersomnia with “sleep drunkenness”.  Arch Gen Psychiatry. 1972;  26 456-462
  PubMedGoogle Scholar
• 24 Sforza E, Gaudreau H, Petit D, Montplaisir J. Homeostatic sleep regulation in patients with idiopathic hypersomnia.  Clin Neurophysiol. 2000;  111 277-282
  CrossrefPubMedGoogle Scholar
• 25 Sangal R B, Sangal J M. P300 latency: abnormal in sleep apnea with somnolence and idiopathic hypersomnia, but normal in narcolepsy.  Clin Electroencephalogr. 1995;  26 146-153
  PubMedGoogle Scholar
• 26 Critchley M. The syndrome of hypersomnia and periodical megaphagia in the adult male (Kleine-Levin): what is its natural course?.  Rev Neurol. 1967;  116 647-650
  PubMedGoogle Scholar
• 27 Rosenow F, Kotagal P, Cohen B H, Green C, Wyllie E. Multiple sleep latency test and polysomnography in diagnosing Kleine-Levin syndrome and periodic hypersomnia.  J Clin Neurophysiol. 2000;  17 519-522
  PubMedGoogle Scholar
• 28 Arias M, Crespo Iglesias J M, Perez J, Requena-Caballero I, Sesar-Ignacio A, Peleteiro-Fernandez M. Klein-Levin syndrome: contribution of brain SPECT in diagnosis.  Rev Neurol. 2003;  35 531-533
  PubMedGoogle Scholar
• 29 Billiard M, Guilleminault C, Dement W C. A menstruation-linked periodic hypersomnia. Kleine-Levin syndrome or a new clinical entity?.  Neurology. 1975;  25 436-443
  PubMedGoogle Scholar
• 30 Sachs C, Persson H, Hagenfeldt K. Menstruation-associated periodic hypersomnia: a case study with successful treatment.  Neurology. 1982;  32 1376-1379
  PubMedGoogle Scholar
• 31 Bamford C R. Menstrual-associated sleep disorder: an unusual hypersomniac variant associated with both menstruation and amenorrhea with a possible link to prolactin and metoclopramide.  Sleep. 1993;  16 484-486
  PubMedGoogle Scholar
• 32 Rothstein J D, Guidotti A, Tinuper P et al.. Endogenous benzodiazepine receptor ligands in idiopathic recurring stupor.  Lancet. 1992;  340 1002-1004
  CrossrefPubMedGoogle Scholar
• 33 Lugaresi E, Montagna P, Tinuper P et al.. Endozepine stupor. Recurring stupor linked to endozepine-4 accumulation.  Brain. 1998;  121 127-133
  CrossrefPubMedGoogle Scholar
• 34 Soriani S, Carrozzi M, De Carlo L et al.. Endozepine stupor in children.  Cephalalgia. 1997;  17 658-661
  CrossrefPubMedGoogle Scholar
• 35 Francisco G E, Ivanhoe C B. Successful treatment of post-traumatic narcolepsy with methylphenidate: a case report.  Am J Phys Med Rehabil. 1996;  75 63-65
  CrossrefPubMedGoogle Scholar
• 36 Manni R, Tantara A. Evaluation of sleepiness in epilepsy.  Clin Neurophysiol. 2000;  111(suppl 2) S111-S114
  CrossrefPubMedGoogle Scholar
• 37 Toth L A, Opp M R. Sleep and infection. In: Lee-Chiong TL, Sateia MJ, Carskadon MA Sleep Medicine Philadelphia; Hanley & Belfus 2002: 77-83
  Google Scholar
• 38 Guilleminault C, Mondini S. Mononucleosis and chronic daytime sleepiness: a long term follow-up study.  Arch Intern Med. 1986;  146 1333-1335
  CrossrefPubMedGoogle Scholar
• 39 Askenasy J JM. Sleep in Parkinson’s disease.  Acta Neurol Scand. 1993;  87 167-170
  PubMedGoogle Scholar
• 40 Chokroverty S. Sleep and degenerative neurologic disorders.  Neurol Clin. 1996;  14 807-826
  CrossrefPubMedGoogle Scholar
• 41 Trenkwalder C. Sleep dysfunction in Parkinson’s disease.  Clin Neurosci. 1998;  5 107-114
  PubMedGoogle Scholar
• 42 George C FP. Neuromuscular disorders. In: Kryger MH, Roth T, Dement WC Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia; WB Saunders Co 2000: 1087-1092
  Google Scholar
• 43 Gibbs J W, Ciafaloni E, Radtke R A. Excessive daytime somnolence and increased rapid eye movement pressure in myotonic dystrophy.  Sleep. 2002;  25 672-675
  PubMedGoogle Scholar
• 44 Mitler M M, Aldrich M S, Koob G F, Zarcone V P. Narcolepsy and its treatment with stimulants. ASDA Standards of Practice.  Sleep. 1994;  17 352-371
  PubMedGoogle Scholar
• 45 US Modafinil in Narcolepsy Multicenter Study Group . Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy.  Neurology. 2000;  54 1166-1175
  CrossrefPubMedGoogle Scholar
• 46 US Modafinil in Narcolepsy Multicenter Study Group . Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy.  Ann Neurol. 1998;  43 88-97
  CrossrefPubMedGoogle Scholar
• 47 Tunnicliff G, Cash C D. Gamma-hydroxybutyrate: Molecular, Functional and Clinical Aspects. New York; Taylor and Francis 2002
  Google Scholar
• 48 Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy.  Prog Neurobiol. 1997;  52 27-78
  CrossrefPubMedGoogle Scholar
• 49 Dement W, Rechtschaffen A, Gulevich G. The nature of the narcoleptic sleep attack.  Neurology. 1966;  16 18-33
  PubMedGoogle Scholar
• 50 Broughton R, Valley V, Aguirre M, Roberts J, Suwalski W, Dunham W. Excessive daytime sleepiness and pathophysiology of narcolepsy-cataplexy: a laboratory perspective.  Sleep. 1986;  9 205-215
  PubMedGoogle Scholar
• 51 Guilleminault C, Wilson R A, Dement W C. A study on cataplexy.  Arch Neurol. 1974;  31 255-261
  PubMedGoogle Scholar
• 52 Nishino S, Riehl J, Hong J, Kwan M, Reid M, Mignot E. Is narcolepsy REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans.  Neurosci Res. 2000;  38 437-446
  CrossrefPubMedGoogle Scholar
• 53 Mignot E, Lammers G J, Ripley B et al.. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.  Arch Neurol. 2002;  59 1553-1562
  CrossrefPubMedGoogle Scholar
• 54 Fukuda K, Miyasita A, Inugami M, Ishihara K. High prevalence of isolated sleep paralysis: Kanashibari phenomenon in Japan.  Sleep. 1987;  10 279-286
  PubMedGoogle Scholar
• 55 Bishop C, Rosenthal L, Helmus T, Roehrs T, Roth T. The frequency of multiple sleep onset REM periods among subjects with no excessive daytime sleepiness.  Sleep. 1996;  19 727-730
  PubMedGoogle Scholar
• 56 Ohayon M M, Priest R G, Caulet M, Guilleminault C. Hypnagogic and hypnopompic hallucinations: pathological phenomena?.  Br J Psychiatry. 1996;  169 459-467
  CrossrefPubMedGoogle Scholar
• 57 Aldrich M S, Chervin R D, Malow B A. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy.  Sleep. 1997;  20 620-629
  PubMedGoogle Scholar
• 58 Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive.  Tissue Antigens. 1984;  24 316-319
  CrossrefPubMedGoogle Scholar
• 59 Mignot E, Hayduk R, Black J, Grumet F C, Guilleminault C. HLA Class II studies in 509 narcoleptic patients.  Sleep Res. 1997;  26 433
  PubMedGoogle Scholar
• 60 Mignot E, Guilleminault C, Grumet F C, Dement W C. Is narcolepsy an autoimmune disease?. In: Smirne S, Francesci M, Ferini-Strambi L, Zucconi M Proceedings of the Third Milano International Symposium, September 18-19. “Sleep, Hormones, and the Immune System” Milan; Masson 1992: 29-38
  Google Scholar
• 61 Frederickson S, Carlander B, Billiard M, Link H. CSF immune variable in patients with narcolepsy.  Acta Neurol Scand. 1990;  81 253-254
  PubMedGoogle Scholar
• 62 Matsuki K, Juji T, Honda Y. Immunological features of narcolepsy in Japan. In: Honda Y, Juji T HLA in Narcolepsy Berlin; Springer-Verlag 1988: 150-157
  Google Scholar
• 63 Billiard M, Laaberki M F, Reygrobellet C, Seignalet J, Brissaud L, Besset A. Elevated antibodies to streptococcal antigens in narcoleptic subjects.  Sleep Res. 1989;  18 201
  PubMedGoogle Scholar
• 64 Montplaisir J, Poirier G, Lapierre O, Montplaisir S. Streptococcal antibodies in narcolepsy and idiopathic hypersomnia.  Sleep Res. 1989;  18 271
  PubMedGoogle Scholar
• 65 Mignot E, Wang C, Rattazzi C et al.. Genetic linkage of autosomal recessive canine narcolepsy with an immunoglobulin heavy-chain switch-like segment.  Proc Natl Acad Sci USA. 1991;  88 3475-3478
  PubMedGoogle Scholar
• 66 Chemelli R M, Willie J T, Sinton C M et al.. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.  Cell. 1999;  98 437-451
  CrossrefPubMedGoogle Scholar
• 67 Lin L, Faraco J, Li R et al.. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.  Cell. 1999;  98 365-376
  CrossrefPubMedGoogle Scholar
• 68 Peyron C, Faraco J, Rogers W et al.. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.  Nat Med. 2000;  6 991-997
  CrossrefPubMedGoogle Scholar
• 69 Nishino S, Ripley B, Overeem S, Lammers G J, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy.  Lancet. 2000;  355 39-40
  CrossrefPubMedGoogle Scholar
• 70 Nishino S, Ripley B, Overeem S et al.. Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy.  Ann Neurol. 2001;  50 381-388
  CrossrefPubMedGoogle Scholar
• 71 Kanbayashi T, Inoue Y, Chiba S et al.. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia.  J Sleep Res. 2002;  11 91-93
  CrossrefPubMedGoogle Scholar
• 72 Krahn L E, Pankratz V S, Oliver L, Boeve B F, Silber M H. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status.  Sleep. 2002;  25 733-736
  PubMedGoogle Scholar
• 73 Thannickal T C, Moore R Y, Nienhuis R et al.. Reduced number of hypocretin neurons in human narcolepsy.  Neuron. 2000;  27 469-474
  CrossrefPubMedGoogle Scholar
• 74 Ripley B, Fujiki N, Okura M, Mignot E, Nishino S. Hypocretin levels in sporadic and familial cases of canine narcolepsy.  Neurobiol Dis. 2001;  8 525-534
  CrossrefPubMedGoogle Scholar
• 75 Ripley B, Overeem S, Fujiki N et al.. CSF hypocretin levels in various neurological conditions: low levels in narcolepsy and Guillain-Barre syndrome.  Sleep. 2001b;  24 A322
  PubMedGoogle Scholar
• 76 Alaila S L. Life effects of narcolepsy: measures of negative impact, social support and psychological well-being. In: Goswanmi M, Pollak CP, Cohen FL, Thorpy MJ, Kavey NB Loss, Grief and Care: Psychosocial Aspects of Narcolepsy New York; Haworth Press 1992: 1-22
  Google Scholar
• 77 De Lecea L, Kilduff T S, Peyron C et al.. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.  Proc Natl Acad Sci USA. 1998;  95 322-327
  CrossrefPubMedGoogle Scholar
• 78 Sakurai T, Amemiya A, Ishil M et al.. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein coupled receptors that regulate feeding behavior.  Cell. 1998;  92 573-585
  CrossrefPubMedGoogle Scholar
• 79 Peyron C, Tighe D K, van den Pol A N et al.. Neurons containing hypocretin (orexin) project to multiple neuronal systems.  J Neurosci. 1998;  18 9996-10015
  PubMedGoogle Scholar
• 80 Willie J T, Chemelli R M, Sinton C M, Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness.  Annu Rev Neurosci. 2001;  24 429-458
  CrossrefPubMedGoogle Scholar
• 81 Taheri S, Zeitzer J M, Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy.  Annu Rev Neurosci. 2002;  25 283-313
  CrossrefPubMedGoogle Scholar
• 82 Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy.  Prog Neurobiol. 1997;  52 27-78
  CrossrefPubMedGoogle Scholar
• 83 Eriksson K S, Sergeeva O, Brown R E, Haas H L. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus.  J Neurosci. 2001;  21 9273-9279
  CrossrefPubMedGoogle Scholar
• 84 Huang Z L, Qu W M, Li W D et al.. Arousal effect of orexin A depends on activation of the histaminergic system.  Proc Natl Acad Sci USA. 2001;  98 9965-9970
  CrossrefPubMedGoogle Scholar
• 85 Yamanaka A, Tsujino N, Funahashi H et al.. Orexins activate histaminergic neurons via the orexin 2 receptor.  Biochem Biophys Res Commun. 2002;  290 1237-1245
  CrossrefPubMedGoogle Scholar
• 86 Nishino S, Fujiki N, Ripley B et al.. Decreased brain histamine contents in hypocretin/orexin receptor-2 mutated narcoleptic dogs.  Neurosci Lett. 2001;  313 125-128
  CrossrefPubMedGoogle Scholar
• 87 Tedford C E, Edgar D M, Seidel W F et al.. Effects of a novel, selective, and potent histamine H3 receptor antagonist, GT-2332, on rat sleep/wakefulness and canine cataplexy.  Soc Neurosci Abstr. 1999;  25 1134
  PubMedGoogle Scholar
• 88 Fujiki N, Yoshida Y, Ripley B, Honda K, Mignot E, Nishino S. Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation.  Neuroreport. 2001;  12 993-997
  PubMedGoogle Scholar
• 89 Yoshida Y, Fujiki N, Nakajima T et al.. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities.  Eur J Neurosci. 2001;  14 1075-1081
  CrossrefPubMedGoogle Scholar
• 90 Zeitzer J M, Buckmaster C L, Parker K J, Hauck C M, Lyons D M, Mignot E. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness.  J Neurosci. 2003;  23 3555-3560
  PubMedGoogle Scholar
• 91 Aston-Jones G, Chen S, Zhu Y, Oshinsky M L. A neural circuit for circadian regulation of arousal.  Nat Neurosci. 2001;  4 732-738
  CrossrefPubMedGoogle Scholar
• 92 Wu M F, John J, Maidment N, Lam H A, Siegel J M. Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement.  Am J Physiol Regul Integr Comp Physiol. 2002;  283 R1079-R1086
  PubMedGoogle Scholar

Jed E BlackM.D. 

Department of Psychiatry and Behavioral Sciences, Stanford University

401 Quarry Road, #3301, Stanford

CA 94305